JP2023530704A5 - - Google Patents
Info
- Publication number
- JP2023530704A5 JP2023530704A5 JP2022577426A JP2022577426A JP2023530704A5 JP 2023530704 A5 JP2023530704 A5 JP 2023530704A5 JP 2022577426 A JP2022577426 A JP 2022577426A JP 2022577426 A JP2022577426 A JP 2022577426A JP 2023530704 A5 JP2023530704 A5 JP 2023530704A5
- Authority
- JP
- Japan
- Prior art keywords
- derived
- car
- cells
- receptor
- ipsc
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202063041672P | 2020-06-19 | 2020-06-19 | |
| US63/041,672 | 2020-06-19 | ||
| PCT/US2021/038134 WO2021258016A1 (en) | 2020-06-19 | 2021-06-18 | Combining ipsc-derived effector cell types for immunotherapy use |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2023530704A JP2023530704A (ja) | 2023-07-19 |
| JP2023530704A5 true JP2023530704A5 (https=) | 2024-06-25 |
Family
ID=79025356
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022577426A Pending JP2023530704A (ja) | 2020-06-19 | 2021-06-18 | 免疫療法で使用するためのｉＰＳＣ由来エフェクター細胞型の組み合わせ |
Country Status (11)
| Country | Link |
|---|---|
| US (2) | US12275955B2 (https=) |
| EP (1) | EP4168538A4 (https=) |
| JP (1) | JP2023530704A (https=) |
| KR (1) | KR20230040337A (https=) |
| CN (1) | CN116096386A (https=) |
| AU (1) | AU2021292695A1 (https=) |
| BR (1) | BR112022025806A2 (https=) |
| CA (1) | CA3182852A1 (https=) |
| IL (1) | IL299106B1 (https=) |
| MX (1) | MX2022015863A (https=) |
| WO (1) | WO2021258016A1 (https=) |
Families Citing this family (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR20230118887A (ko) | 2020-12-03 | 2023-08-14 | 센츄리 쎄라퓨틱스 인코포레이티드 | 유전자 조작 세포 및 이의 용도 |
| US11661459B2 (en) | 2020-12-03 | 2023-05-30 | Century Therapeutics, Inc. | Artificial cell death polypeptide for chimeric antigen receptor and uses thereof |
| AR124414A1 (es) * | 2020-12-18 | 2023-03-22 | Century Therapeutics Inc | Sistema de receptor de antígeno quimérico con especificidad de receptor adaptable |
| AU2022423987A1 (en) * | 2021-12-29 | 2024-07-11 | Century Therapeutics, Inc. | Genetically engineered cells having anti-cd19 / anti-cd22 chimeric antigen receptors, and uses thereof |
| EP4508193A4 (en) * | 2022-04-11 | 2026-04-29 | In8Bio Inc | IPSC-BASED GAMMA-DELTA T LYMPHOCYTES: COMPOSITIONS AND METHODS OF USE |
| CN116948012B (zh) * | 2022-04-13 | 2024-07-26 | 星奕昂(上海)生物科技有限公司 | 增强细胞功能的cd16抗剪切突变体 |
| US20250090582A1 (en) * | 2022-06-08 | 2025-03-20 | Century Therapeutics, Inc. | Genetically engineered cells having anti-cd133 / anti-egfr chimeric antigen receptors, and uses thereof |
| CN117305241B (zh) * | 2023-11-28 | 2024-03-19 | 上海兴瑞一达生物科技有限公司 | 一种hiPSCs诱导分化为NK细胞的方法 |
| CN118389421A (zh) * | 2024-04-01 | 2024-07-26 | 苏州艾凯利元生物科技有限公司 | 一种体外评估nk细胞群的特性的方法 |
| WO2026073244A1 (en) * | 2024-09-30 | 2026-04-02 | Ensoma, Inc. | Constructs for multi-lineage expression of therapeutic agents |
Family Cites Families (37)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6352694B1 (en) | 1994-06-03 | 2002-03-05 | Genetics Institute, Inc. | Methods for inducing a population of T cells to proliferate using agents which recognize TCR/CD3 and ligands which stimulate an accessory molecule on the surface of the T cells |
| GB9710809D0 (en) | 1997-05-23 | 1997-07-23 | Medical Res Council | Nucleic acid binding proteins |
| GB9710807D0 (en) | 1997-05-23 | 1997-07-23 | Medical Res Council | Nucleic acid binding proteins |
| US6140081A (en) | 1998-10-16 | 2000-10-31 | The Scripps Research Institute | Zinc finger binding domains for GNN |
| US6534261B1 (en) | 1999-01-12 | 2003-03-18 | Sangamo Biosciences, Inc. | Regulation of endogenous gene expression in cells using zinc finger proteins |
| US6453242B1 (en) | 1999-01-12 | 2002-09-17 | Sangamo Biosciences, Inc. | Selection of sites for targeting by zinc finger proteins and methods of designing zinc finger proteins to bind to preselected sites |
| JP2002060786A (ja) | 2000-08-23 | 2002-02-26 | Kao Corp | 硬質表面用殺菌防汚剤 |
| JP2005500061A (ja) | 2001-08-20 | 2005-01-06 | ザ スクリップス リサーチ インスティテュート | Ｃｎｎについての亜鉛フィンガー結合ドメイン |
| US7745140B2 (en) | 2002-01-03 | 2010-06-29 | The Trustees Of The University Of Pennsylvania | Activation and expansion of T-cells using an engineered multivalent signaling platform as a research tool |
| US7888121B2 (en) | 2003-08-08 | 2011-02-15 | Sangamo Biosciences, Inc. | Methods and compositions for targeted cleavage and recombination |
| US7972854B2 (en) | 2004-02-05 | 2011-07-05 | Sangamo Biosciences, Inc. | Methods and compositions for targeted cleavage and recombination |
| WO2005118788A2 (en) | 2004-05-27 | 2005-12-15 | The Trustees Of The University Of Pennsylvania | Novel artificial antigen presenting cells and uses therefor |
| NZ573646A (en) | 2006-06-12 | 2012-04-27 | Wyeth Llc | Single-chain multivalent binding proteins with effector function |
| WO2011072246A2 (en) | 2009-12-10 | 2011-06-16 | Regents Of The University Of Minnesota | Tal effector-mediated dna modification |
| WO2011159726A2 (en) | 2010-06-14 | 2011-12-22 | The Scripps Research Institute | Reprogramming of cells to a new fate |
| MX2014001222A (es) | 2011-07-29 | 2014-09-15 | Univ Pennsylvania | Receptores coestimuladores de cambio. |
| CA2861491C (en) | 2012-02-13 | 2020-08-25 | Seattle Children's Hospital D/B/A Seattle Children's Research Institute | Bispecific chimeric antigen receptors and therapeutic uses thereof |
| BR112014029417B1 (pt) | 2012-05-25 | 2023-03-07 | Cellectis | Método ex vivo para a preparação de células t para imunoterapia |
| DK2956175T3 (da) | 2013-02-15 | 2017-11-27 | Univ California | Kimærisk antigenreceptor og fremgangsmåder til anvendelse deraf |
| WO2014165707A2 (en) * | 2013-04-03 | 2014-10-09 | Memorial Sloan-Kettering Cancer Center | Effective generation of tumor-targeted t-cells derived from pluripotent stem cells |
| US9932607B2 (en) | 2013-11-15 | 2018-04-03 | The Board Of Trustees Of The Leland Stanford Junior University | Site-specific integration of transgenes into human cells |
| US10934346B2 (en) | 2014-02-14 | 2021-03-02 | Bellicum Pharmaceuticals, Inc. | Modified T cell comprising a polynucleotide encoding an inducible stimulating molecule comprising MyD88, CD40 and FKBP12 |
| KR102375998B1 (ko) | 2014-02-14 | 2022-03-21 | 더 보드 오브 리젠츠 오브 더 유니버시티 오브 텍사스 시스템 | 키메라 항원 수용체 및 제조방법 |
| CA2941004A1 (en) | 2014-03-04 | 2015-09-11 | Peter Flynn | Improved reprogramming methods and cell culture platforms |
| PT3122769T (pt) * | 2014-03-28 | 2023-04-24 | Univ Minnesota | Polipéptidos, células e métodos que envolvem cd16 manipulado |
| AU2015312117A1 (en) | 2014-09-02 | 2017-03-02 | Bellicum Pharmaceuticals, Inc. | Costimulation of chimeric antigen receptors by Myd88 and CD40 polypeptides |
| CN117737124A (zh) | 2015-10-16 | 2024-03-22 | 菲特治疗公司 | 用于诱导和维护基态多能性的平台 |
| KR20250141836A (ko) * | 2015-11-04 | 2025-09-29 | 페이트 세러퓨틱스, 인코포레이티드 | 만능 세포의 유전자 조작 |
| SG11201803145RA (en) | 2015-11-04 | 2018-05-30 | Fate Therapeutics Inc | Methods and compositions for inducing hematopoietic cell differentiation |
| US20170166877A1 (en) | 2015-12-14 | 2017-06-15 | Bellicum Pharmaceuticals, Inc. | Dual controls for therapeutic cell activation or elimination |
| JP7653759B2 (ja) | 2016-01-20 | 2025-03-31 | フェイト セラピューティクス，インコーポレイテッド | 養子免疫療法における免疫細胞調節のための組成物および方法 |
| JP7554670B2 (ja) | 2017-10-11 | 2024-09-20 | フェイト セラピューティクス，インコーポレイテッド | 一時的かつ一過性プラスミドベクター発現システムを用いる細胞のリプログラミング |
| JP2021505131A (ja) | 2017-12-08 | 2021-02-18 | フェイト セラピューティクス，インコーポレイテッド | 増強されたｉＰＳＣ由来のエフェクター細胞を用いた免疫療法 |
| IL316257A (en) | 2017-12-22 | 2024-12-01 | Fate Therapeutics Inc | Enhanced immune effector cells and use thereof |
| KR102817092B1 (ko) * | 2018-03-29 | 2025-06-09 | 페이트 세러퓨틱스, 인코포레이티드 | 조작된 면역 효과기 세포 및 이의 용도 |
| MX2021006194A (es) * | 2018-12-02 | 2021-06-30 | Fate Therapeutics Inc | Inmunoterapias mediante el uso de celulas efectoras potenciadas derivadas de ipsc. |
| KR20210139472A (ko) | 2019-04-11 | 2021-11-22 | 페이트 세러퓨틱스, 인코포레이티드 | 조작된 iPSC 및 면역 효과기 세포에서의 CD3 재구성 |
-
2021
- 2021-06-18 BR BR112022025806A patent/BR112022025806A2/pt unknown
- 2021-06-18 CN CN202180055596.3A patent/CN116096386A/zh active Pending
- 2021-06-18 EP EP21824823.5A patent/EP4168538A4/en active Pending
- 2021-06-18 JP JP2022577426A patent/JP2023530704A/ja active Pending
- 2021-06-18 MX MX2022015863A patent/MX2022015863A/es unknown
- 2021-06-18 WO PCT/US2021/038134 patent/WO2021258016A1/en not_active Ceased
- 2021-06-18 AU AU2021292695A patent/AU2021292695A1/en active Pending
- 2021-06-18 CA CA3182852A patent/CA3182852A1/en active Pending
- 2021-06-18 US US18/002,248 patent/US12275955B2/en active Active
- 2021-06-18 KR KR1020237001980A patent/KR20230040337A/ko active Pending
-
2022
- 2022-12-14 IL IL299106A patent/IL299106B1/en unknown
-
2025
- 2025-03-14 US US19/080,511 patent/US20250313802A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2023530704A5 (https=) | ||
| JP2022541441A5 (https=) | ||
| JP2021505131A5 (https=) | ||
| JP2022550899A5 (https=) | ||
| JP2022510207A5 (https=) | ||
| JP2022548943A5 (https=) | ||
| JP2023505206A5 (https=) | ||
| US20260055157A1 (en) | Methods of making chimeric antigen receptor-expressing cells | |
| JP2023549098A5 (https=) | ||
| JP2021519061A5 (https=) | ||
| JP2023548467A5 (https=) | ||
| JP7623020B2 (ja) | 同種異系移植のための操作された免疫細胞 | |
| JP2023548829A5 (https=) | ||
| JP2024518011A5 (https=) | ||
| KR102600544B1 (ko) | 트랜스진 유전자 태그 및 사용 방법 | |
| JP2023545992A5 (https=) | ||
| JP2024518011A (ja) | 多様な免疫細胞のための単鎖および多鎖合成抗原受容体 | |
| CA3107675A1 (en) | Improving the efficacy and safety of adoptive cellular therapies | |
| JP2022527405A5 (https=) | ||
| US11760806B2 (en) | CD-38 directed chimeric antigen receptor constructs | |
| CA3032054A1 (en) | Combination therapies of chimeric antigen receptors and pd-1 inhibitors | |
| KR20230129983A (ko) | 조작된 세포 요법을 위한 표적화된 사이토카인 구축물 | |
| CN114015656A (zh) | 用于同种异体移植的工程化免疫细胞 | |
| WO2020057641A1 (zh) | 表达有趋化因子的细胞及用途 | |
| EP3909590A1 (en) | Cellular immunotherapy combination |